International Journal of Cancer Management

Published by: Kowsar

The Role of 22 Genes Expression in Bladder Cancer by Adaptive LASSO

Hadi Raeisi Shahraki 1 , Mansooreh Jaberipoor 2 , Najaf Zare 1 , 3 , * and Ahmad Hosseini 2
Authors Information
1 Department of Biostatistics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2 Cancer Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3 Infertility Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Article information
  • Iranian Journal of Cancer Prevention: December 2016, 9 (6); e5051
  • Published Online: December 24, 2016
  • Article Type: Research Article
  • Received: January 2, 2016
  • Revised: March 2, 2016
  • Accepted: December 3, 2016
  • DOI: 10.17795/ijcp-5051

To Cite: Raeisi Shahraki H, Jaberipoor M, Zare N, Hosseini A. The Role of 22 Genes Expression in Bladder Cancer by Adaptive LASSO, Int J Cancer Manag. 2016 ;9(6):e5051. doi: 10.17795/ijcp-5051.

Abstract
Copyright © 2016, Iranian Journal of Cancer Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Andrew AS, Gui J, Sanderson AC, Mason RA, Morlock EV, Schned AR, et al. Bladder cancer SNP panel predicts susceptibility and survival. Hum Genet. 2009; 125(5-6): 527-39[DOI][PubMed]
  • 2. Mohammad-Beigi A, Rezaeeianzadeh A, Tabbatabaei HR. Application of life table in survival analysis of patients with bladder cancer. Zahedan J Res Med Sci. 2011; 13(3): 25-9
  • 3. Sanderson S, Salanti G, Higgins J. Joint effects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes and smoking on bladder carcinogenesis: a literature-based systematic HuGE review and evidence synthesis. Am J Epidemiol. 2007; 166(7): 741-51[DOI][PubMed]
  • 4. Wallace DM, Raghavan D, Kelly KA, Sandeman TF, Conn IG, Teriana N, et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol. 1991; 67(6): 608-15[PubMed]
  • 5. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25(33): 5287-312[DOI][PubMed]
  • 6. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics. 2012; 13: 134[DOI][PubMed]
  • 7. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, et al. IL-23 promotes tumour incidence and growth. Nature. 2006; 442(7101): 461-5[DOI][PubMed]
  • 8. Huang J, Ma S, Zhang CH. Adaptive Lasso for sparse high-dimensional regression models. Statistica Sinica. 2008; 18(4): 1603
  • 9. Huang J, Ma S, Zhang CH. The iterated lasso for high-dimensional logistic regression. The University of Iowa Department of Statistical and Actuarial Science Technical Report. 2008; (392)
  • 10. Gosalbez M, Hupe MC, Lokeshwar SD, Yates TJ, Shields J, Veerapen MK, et al. Differential expression of SDF-1 isoforms in bladder cancer. J Urol. 2014; 191(6): 1899-905[DOI][PubMed]
  • 11. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001; 19: 565-94[DOI][PubMed]
  • 12. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005; 201(2): 233-40[DOI][PubMed]
  • 13. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3(5): 541-7[PubMed]
  • 14. Lae M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol. 2010; 21(4): 815-9[DOI][PubMed]
  • 15. Tetu B, Fradet Y, Allard P, Veilleux C, Roberge N, Bernard P. Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer. J Urol. 1996; 155(5): 1784-8[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments